Vertex Pharmaceuticals (NASDAQ:VRTX) PT Lowered to $466.00

Vertex Pharmaceuticals (NASDAQ:VRTX) had its price objective decreased by UBS Group from $498.00 to $466.00 in a research note released on Wednesday morning, Benzinga reports. UBS Group currently has a buy rating on the pharmaceutical company’s stock.

Other analysts have also recently issued research reports about the company. Guggenheim lifted their price objective on Vertex Pharmaceuticals from $445.00 to $450.00 and gave the stock a buy rating in a research report on Thursday. Maxim Group lowered shares of Vertex Pharmaceuticals from a buy rating to a hold rating in a research report on Wednesday, January 31st. Robert W. Baird lowered shares of Vertex Pharmaceuticals from a neutral rating to an underperform rating and set a $325.00 target price on the stock. in a research report on Wednesday, January 31st. William Blair reiterated an outperform rating on shares of Vertex Pharmaceuticals in a research report on Tuesday, February 6th. Finally, Oppenheimer restated an outperform rating and issued a $500.00 price target on shares of Vertex Pharmaceuticals in a report on Monday. Three analysts have rated the stock with a sell rating, six have given a hold rating, fourteen have assigned a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of Moderate Buy and a consensus price target of $429.45.

Vertex Pharmaceuticals Stock Performance

NASDAQ:VRTX opened at $393.10 on Wednesday. Vertex Pharmaceuticals has a fifty-two week low of $316.43 and a fifty-two week high of $448.40. The company has a quick ratio of 3.78, a current ratio of 3.99 and a debt-to-equity ratio of 0.02. The stock has a market cap of $101.60 billion, a PE ratio of 28.30, a price-to-earnings-growth ratio of 1.84 and a beta of 0.35. The firm’s fifty day simple moving average is $414.76 and its 200-day simple moving average is $396.76.

Vertex Pharmaceuticals (NASDAQ:VRTX) last released its quarterly earnings data on Monday, February 5th. The pharmaceutical company reported $4.20 EPS for the quarter, topping the consensus estimate of $3.85 by $0.35. The business had revenue of $2.52 billion for the quarter, compared to analyst estimates of $2.50 billion. Vertex Pharmaceuticals had a net margin of 36.68% and a return on equity of 21.91%. During the same period in the previous year, the firm earned $3.33 EPS. Analysts expect that Vertex Pharmaceuticals will post 15.08 earnings per share for the current fiscal year.

Insider Transactions at Vertex Pharmaceuticals

In other Vertex Pharmaceuticals news, EVP Amit Sachdev sold 3,222 shares of the stock in a transaction on Monday, February 12th. The shares were sold at an average price of $420.24, for a total transaction of $1,354,013.28. Following the sale, the executive vice president now directly owns 74,364 shares of the company’s stock, valued at $31,250,727.36. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In other news, COO Stuart A. Arbuckle sold 4,295 shares of the business’s stock in a transaction that occurred on Monday, February 12th. The stock was sold at an average price of $420.24, for a total transaction of $1,804,930.80. Following the completion of the transaction, the chief operating officer now directly owns 75,718 shares in the company, valued at $31,819,732.32. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, EVP Amit Sachdev sold 3,222 shares of the firm’s stock in a transaction that occurred on Monday, February 12th. The shares were sold at an average price of $420.24, for a total value of $1,354,013.28. Following the completion of the sale, the executive vice president now owns 74,364 shares in the company, valued at $31,250,727.36. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 12,381 shares of company stock valued at $5,203,249. 0.20% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Vertex Pharmaceuticals

Institutional investors and hedge funds have recently bought and sold shares of the stock. OFI Invest Asset Management acquired a new position in shares of Vertex Pharmaceuticals during the third quarter valued at approximately $25,000. University of Texas Texas AM Investment Managment Co. acquired a new stake in Vertex Pharmaceuticals in the fourth quarter worth approximately $25,000. Arlington Trust Co LLC boosted its stake in Vertex Pharmaceuticals by 97.1% during the 4th quarter. Arlington Trust Co LLC now owns 67 shares of the pharmaceutical company’s stock valued at $27,000 after purchasing an additional 33 shares in the last quarter. Annapolis Financial Services LLC acquired a new stake in shares of Vertex Pharmaceuticals in the first quarter valued at $27,000. Finally, ICA Group Wealth Management LLC acquired a new stake in Vertex Pharmaceuticals during the fourth quarter valued at approximately $28,000. Institutional investors own 90.96% of the company’s stock.

About Vertex Pharmaceuticals

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.